Physician profile
Hemali Kumar
NPI 1548743388
$731.32
in general payments reported to CMS, 2019-2025
14 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $140 · 2023: $110 · 2024: $46.97 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $133.60 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.70 | 2021-2024 | Entyvio |
| Janssen Biotech, INC. | $99.99 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.53 | 2021-2025 | Xifaxan |
| Celgene Corporation | $42.41 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $42.30 | 2022 | |
| Nestle Healthcare Nutrition INC. | $41.50 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $38.73 | 2025 | Voquezna |
| Genzyme Corporation | $26.96 | 2025 | |
| Aimmune Therapeutics, INC. | $26.12 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $25.14 | 2023 | Dificid |
| Celltrion USA INC. | $19.46 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $17.20 | 2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $14.68 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemali Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.